COVID19 Chronic Morbidity: Follow-up of patients with COVID19 and non-COVID19 pneumonia with respect to clinical status, pulmonary function and radiologic findings

COVID19 Chronic Morbidity: Follow-up of patients with COVID19 and non-COVID19 pneumonia with respect to clinical status, pulmonary function and radiologic findings - CCHROMO

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022475

Enrollment

500

Registered

2020-07-27

Start date

2020-08-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Disease 19 (COVID19) U07.1 J12 J13 J14 J15 J16 J17 J18

Interventions

Group 1: Patients following COVID19: Evaluation of data obtained during clinical follow up examinations of COVID patients up to one year after disease (data recorded at 1-2, 3, 6, 9 and 12 months afte

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients after SARS-CoV2 infection or community-acquired pneumonia - age >= 18 years - written informed consent

Exclusion criteria

Exclusion criteria: - pregnancy - for non-COVID19 pneumonia: hospitalisation >48h prior to diagnosis

Design outcomes

Primary

Measure	Time frame
As the long-term consequences of COVID19 are not yet known, this study is intended as an exploratory analysis of different aspects. A formal separation into primary and secondary outcome measures will therefore not be made. The following aspects will be investigated in this study - Oxygenation (Horovitz index 1,3,6,9, and 12 months after diagnosis) - static/dynamic lung volumes - gas exchange (capillary blood gas analysis, diffusing capacity, total oxygen uptake, total oxygen uptake during spiroergometry) - symptoms (e.g., 18-item community-acquired pneumonia symptom questionnaire, dyspnoea [mMRC scale]) - occurence of exacerbations of previously known pulmonary disases (COPD, asthma, ILD) - medication - quality of life (36-item short form survey) - development of pathogen-specific antibodies	—

Measure

Time frame

As the long-term consequences of COVID19 are not yet known, this study is intended as an exploratory analysis of different aspects. A formal separation into primary and secondary outcome measures will therefore not be made. The following aspects will be investigated in this study - Oxygenation (Horovitz index 1,3,6,9, and 12 months after diagnosis) - static/dynamic lung volumes - gas exchange (capillary blood gas analysis, diffusing capacity, total oxygen uptake, total oxygen uptake during spiroergometry) - symptoms (e.g., 18-item community-acquired pneumonia symptom questionnaire, dyspnoea [mMRC scale]) - occurence of exacerbations of previously known pulmonary disases (COPD, asthma, ILD) - medication - quality of life (36-item short form survey) - development of pathogen-specific antibodies

—

Secondary

Measure	Time frame
/ (see above)	—

Countries

Germany

Contacts

Public ContactGernot Rohde

Universitätsklinikum Frankfurt

pneumo.studien@kgu.de069-63016336

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 18, 2026